Investigation of the reconsultation rate and pharmacoeconomic evaluation of period of influenza treatment by oseltamivir

Katsunori Yamaura, Masayoshi Yoshihara

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In the epidemic of influenza in fiscal 2002, there was a shortage in Japan of the anti-influenza virus medicine "oseltamivir". For this reason, many medical institutions were forced to shorten the treatment period with this medication. In this study, we compared the shorter oseltamivir treatment and the indicated 5-day course of treatment with the index for the reconsultation rate and medication dispensing fee from the viewpoint of pharmacoeconomics and clinical effect. Oseltamivir was prescribed for 2, 3 or 5 days for the treatment of influenza, and the rate of reconsultation, type of virus and age were analyzed. The total fees paid to a pharmacy for influenza treatment were also calculated for pharmacoeconomic evaluation. Two-day treated patients had a higher rate of reconsultation compared with the 3- and 5-day treatment groups. Analysis of patients by influenza virus type and age showed no significant difference in reconsultation rate. The total medication dispensing fees for 2-, 3- and 5-day treatment with oseltamivir were 4713, 4755 and 6520 yen, respectively, that of 5-day treatment being significantly higher. These results suggest that 2-day treatment by oseltamivir was significantly high in reconsultation rate, and 5-day treatment was significantly high in medication dispensing fee, so 3-day treatment of influenza by this medicine is the most suitable from the viewpoint of pharmacoeconomics and clinical effect.

Original languageEnglish
Pages (from-to)887-891
Number of pages5
JournalYakugaku zasshi : Journal of the Pharmaceutical Society of Japan
Volume123
Issue number10
DOIs
Publication statusPublished - 2003 Oct
Externally publishedYes

Fingerprint

Oseltamivir
Pharmaceutical Economics
Human Influenza
Prescription Fees
Therapeutics
Orthomyxoviridae
Medicine
Fees and Charges
Japan

Keywords

  • Influenza
  • Oseltamivir
  • Pharmacoeconomics
  • Prescription
  • Reconsultation rate

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

@article{9b88972ef9924d0ca92840fd3a166032,
title = "Investigation of the reconsultation rate and pharmacoeconomic evaluation of period of influenza treatment by oseltamivir",
abstract = "In the epidemic of influenza in fiscal 2002, there was a shortage in Japan of the anti-influenza virus medicine {"}oseltamivir{"}. For this reason, many medical institutions were forced to shorten the treatment period with this medication. In this study, we compared the shorter oseltamivir treatment and the indicated 5-day course of treatment with the index for the reconsultation rate and medication dispensing fee from the viewpoint of pharmacoeconomics and clinical effect. Oseltamivir was prescribed for 2, 3 or 5 days for the treatment of influenza, and the rate of reconsultation, type of virus and age were analyzed. The total fees paid to a pharmacy for influenza treatment were also calculated for pharmacoeconomic evaluation. Two-day treated patients had a higher rate of reconsultation compared with the 3- and 5-day treatment groups. Analysis of patients by influenza virus type and age showed no significant difference in reconsultation rate. The total medication dispensing fees for 2-, 3- and 5-day treatment with oseltamivir were 4713, 4755 and 6520 yen, respectively, that of 5-day treatment being significantly higher. These results suggest that 2-day treatment by oseltamivir was significantly high in reconsultation rate, and 5-day treatment was significantly high in medication dispensing fee, so 3-day treatment of influenza by this medicine is the most suitable from the viewpoint of pharmacoeconomics and clinical effect.",
keywords = "Influenza, Oseltamivir, Pharmacoeconomics, Prescription, Reconsultation rate",
author = "Katsunori Yamaura and Masayoshi Yoshihara",
year = "2003",
month = "10",
doi = "10.1248/yakushi.123.887",
language = "English",
volume = "123",
pages = "887--891",
journal = "Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "10",

}

TY - JOUR

T1 - Investigation of the reconsultation rate and pharmacoeconomic evaluation of period of influenza treatment by oseltamivir

AU - Yamaura, Katsunori

AU - Yoshihara, Masayoshi

PY - 2003/10

Y1 - 2003/10

N2 - In the epidemic of influenza in fiscal 2002, there was a shortage in Japan of the anti-influenza virus medicine "oseltamivir". For this reason, many medical institutions were forced to shorten the treatment period with this medication. In this study, we compared the shorter oseltamivir treatment and the indicated 5-day course of treatment with the index for the reconsultation rate and medication dispensing fee from the viewpoint of pharmacoeconomics and clinical effect. Oseltamivir was prescribed for 2, 3 or 5 days for the treatment of influenza, and the rate of reconsultation, type of virus and age were analyzed. The total fees paid to a pharmacy for influenza treatment were also calculated for pharmacoeconomic evaluation. Two-day treated patients had a higher rate of reconsultation compared with the 3- and 5-day treatment groups. Analysis of patients by influenza virus type and age showed no significant difference in reconsultation rate. The total medication dispensing fees for 2-, 3- and 5-day treatment with oseltamivir were 4713, 4755 and 6520 yen, respectively, that of 5-day treatment being significantly higher. These results suggest that 2-day treatment by oseltamivir was significantly high in reconsultation rate, and 5-day treatment was significantly high in medication dispensing fee, so 3-day treatment of influenza by this medicine is the most suitable from the viewpoint of pharmacoeconomics and clinical effect.

AB - In the epidemic of influenza in fiscal 2002, there was a shortage in Japan of the anti-influenza virus medicine "oseltamivir". For this reason, many medical institutions were forced to shorten the treatment period with this medication. In this study, we compared the shorter oseltamivir treatment and the indicated 5-day course of treatment with the index for the reconsultation rate and medication dispensing fee from the viewpoint of pharmacoeconomics and clinical effect. Oseltamivir was prescribed for 2, 3 or 5 days for the treatment of influenza, and the rate of reconsultation, type of virus and age were analyzed. The total fees paid to a pharmacy for influenza treatment were also calculated for pharmacoeconomic evaluation. Two-day treated patients had a higher rate of reconsultation compared with the 3- and 5-day treatment groups. Analysis of patients by influenza virus type and age showed no significant difference in reconsultation rate. The total medication dispensing fees for 2-, 3- and 5-day treatment with oseltamivir were 4713, 4755 and 6520 yen, respectively, that of 5-day treatment being significantly higher. These results suggest that 2-day treatment by oseltamivir was significantly high in reconsultation rate, and 5-day treatment was significantly high in medication dispensing fee, so 3-day treatment of influenza by this medicine is the most suitable from the viewpoint of pharmacoeconomics and clinical effect.

KW - Influenza

KW - Oseltamivir

KW - Pharmacoeconomics

KW - Prescription

KW - Reconsultation rate

UR - http://www.scopus.com/inward/record.url?scp=15044347790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15044347790&partnerID=8YFLogxK

U2 - 10.1248/yakushi.123.887

DO - 10.1248/yakushi.123.887

M3 - Article

VL - 123

SP - 887

EP - 891

JO - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

JF - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

SN - 0031-6903

IS - 10

ER -